Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 1, 2012, Pages 98-103

  Castro López, Vanessa ^a   Murray, Brian ^a   Harris, Leanne F ^a   O'Donnell, James S ^a,b   Killard, Anthony J ^a,c  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

anticoagulant monitoring; bovine; factor Xa; fluorogenic antifactor Xa assay; human; unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN;

ACCURACY; AMINO ACID SEQUENCE; ARTICLE; CALIBRATION; CHEMICAL REACTION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENZYME KINETICS; FLUORESCENCE; FREEZE DRYING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPRODUCIBILITY; SENSITIVITY ANALYSIS;

ANIMALS; BLOOD COAGULATION TESTS; CATTLE; FACTOR XA; HEPARIN; HUMANS;

EID: 84855203923     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834ddf4d     Document Type: Article

References (21)

1. Bounameaux H. The novel anticoagulants: Entering a new era. Swiss Med Wkly 2009; 139:60-64.
2. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S-203S. (Pubitemid 39297954)
3. Harris LF, Castro-Ló pez V, Hammadi N, O'Donnell JS, Killard AJ. Development of a fluorescent antifactor Xa assay to monitor unfractionated and low molecular weight heparins. Talanta 2010; 81:1725-1730.
4. Smith ML, Wheeler KE. Weight-based heparin protocol using antifactor Xa monitoring. Am J Health Syst Pharm 2010; 67:371-374.
5. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000; 111:397-406.
6. Winkler AM, Sheppard CA, Fantz CR. Laboratory monitoring of heparin: Challenges and opportunities. Lab Med 2007; 38:499-502. (Pubitemid 47206332)
7. Bates SM, Weitz JI. Coagulation assays. Circulation 2005; 112:E53-E60.
8. Lehman CM, Frank EL. Laboratory monitoring of heparin therapy: Partial thromboplastin time or anti-Xa assay? Lab Med 2009; 40:47-51.
9. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring unfractionated heparin (UFH) therapy: Which anti factor xa assay is appropriate? Thromb Res 2007; 120:347-351. (Pubitemid 46879899)
10. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: Relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000; 11:137-144. (Pubitemid 30212853)
11. Ramjee MK. The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation. Anal Biochem 2000; 277:11-18. (Pubitemid 30041755)
12. WHO Expert Committee on Biological Standardization (Fifty-second report). Wld Hlth Org Technol Rep Ser 2004; 924:26.
13. Haginaka J, Seyama C, Murashima T. Retentive and enantioselective properties of ovomucoid-bonded silica columns: Influence of protein purity and isolation method. J Chromatogr A 1995; 704:279-287.
14. Tipton KF. Principles of enzymes assays and kinetic studies. In: Eisenthal R, Danson MJ, editors. Enzyme assays: A practical approach, 1st edn. Oxford: Oxford University Press; 1992. pp. 1-58.
15. Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci 1999; 88:489-500. (Pubitemid 29220973)
16. Morris S, Robey FA, Kosow D. Kinetic studies on the activation of human factor X: The role of metal ions on the reaction catalyzed by the venom coagulant protein of Viper russelli. J Biol Chem 1978; 253:4604-4608. (Pubitemid 8372068)
17. Jackson CM. Factor X. In: Spaet TH, editor. Progress in hemostasis and thrombosis. Orlando: Grune and Stratton; 1984. pp. 55-109.
18. Edwards ST, Betz A, James HL, Thompson E, Yonkovich SJ, Sinha U. Differences between human and rabbit coagulation factor X-implications for in vivo models of thrombosis. Thromb Res 2002; 106:71-79. (Pubitemid 34879968)
19. Kosow D, Furie B, Forasteiri H. Activation of factor X: Kinetic properties of the reaction. Thromb Res 1974; 4:219-227.
20. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications. Thromb Res 2008; 123:396-403.
21. Wagenvoord RJ, Hendrix HH, Hemker HC. Development of a simple chromogenic VIII assay for clinical use. Haemostasis 1989; 19:196-204. (Pubitemid 19202245)